Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Cipla
Cantor Fitzgerald
QuintilesIMS
Deloitte
Express Scripts
Medtronic
Boehringer Ingelheim
Covington

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,761,910

« Back to Dashboard

Summary for Patent: 6,761,910
Title: Pharmaceutical composition for the treatment of acute disorders
Abstract:A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Uppsala, SE)
Assignee: Diabact AB (Uppsala, SE)
Application Number:09/787,888
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,761,910

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-001 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-002 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-003 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-004 Jan 7, 2011 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-005 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-006 Jan 7, 2011 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Sign Up
Mylan Speciality Lp EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-001 Mar 13, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET ➤ Sign Up
Mylan Speciality Lp EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-002 Mar 13, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,761,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803240Sep 24, 1998
PCT Information
PCT FiledSeptember 24, 1999PCT Application Number:PCT/SE99/01687
PCT Publication Date:March 30, 2000PCT Publication Number: WO00/16750

Non-Orange Book US Patents Family Members for Patent 6,761,910

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,910,132 Pharmaceutical composition for the treatment of acute disorders ➤ Sign Up
8,454,996 Pharmaceutical composition for the treatment of acute disorders ➤ Sign Up
8,512,747 Pharmaceutical composition for the treatment of acute disorders ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,761,910

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365540 ➤ Sign Up
Australia 6492799 ➤ Sign Up
Australia 764346 ➤ Sign Up
Bulgaria 105379 ➤ Sign Up
Bulgaria 65502 ➤ Sign Up
Brazil 9913945 ➤ Sign Up
Canada 2345121 ➤ Sign Up
Canada 2629988 ➤ Sign Up
Canada 2820588 ➤ Sign Up
China 1173694 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Deloitte
Boehringer Ingelheim
McKesson
Covington
Cantor Fitzgerald
Merck
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot